Fig. 5.
ATPR regulates the PTEN/PI3K/Akt pathway in human NB4 and THP-1 cells. a NB4 cells were treated with an ATPR concentration gradient (10−5–10−9 M) for 72 h. Then, the protein expression of PTEN, AKT, p-AKT and PI3K was assessed by western blot. b NB4 cells were treated with ATPR (10−6 M) for different durations (0–72 h). Then, the protein expression of PTEN, AKT, p-AKT and PI3K was assessed by western blot. c THP-1 cells were treated with an ATPR concentration gradient (10−5–10−9 M) for 72 h. Then, the protein expression of PTEN, AKT, p-AKT and PI3K was assessed by western blot. d THP-1 cells were treated with ATPR (10−6 M) for different durations (0–72 h). Then, the protein expression of PTEN, AKT, p-AKT and PI3K was assessed by western blot. e NB4 cells were treated with ATPR (10−6 M) for 24 h and 72 h. Immunofluorescence was used to detect p-Akt. *p < 0.05, **p < 0.01 versus control group